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Background: Patients with peripheral arterial disease (PAD) are at high risk of secondary cardiovascular death and events
such as myocardial infarction or stroke. To minimize this elevated risk, cardiovascular risk factors should be treated in all
PAD patients. Secondary risk management may benefit from a prediction tool to identify PAD patients at the highest risk
who could be referred for an additional extensive workup. Stratifying PAD patients according to their risk of secondary
events could aid in achieving optimal therapy compliance. To this end we developed a prediction model for secondary
cardiovascular events in PAD patients.
Methods: The model was developed using data from 800 PAD patients who participated in the Second Manifestations of
ARTerial disease (SMART) cohort study. From the baseline characteristics, 13 candidate predictors were selected for the
model development. Missing values were imputed by means of single regression imputation. Continuous predictors were
truncated and transformed where necessary, followed by model reduction by means of backward stepwise selection. To
correct for over-fitting, a bootstrapping technique was applied. Finally, a score chart was created that divides patients in
four risk categories that have been linked to the risk of a cardiovascular event during 1- and 5-year follow-up.
Results: During a mean follow-up of 4.7 years, 120 events occurred (27% nonfatal myocardial infarction, 21% nonfatal
stroke, and 52% mortality from vascular causes), corresponding to a 1- and 5-year cumulative incidence of 3.1% and
13.2%, respectively. Important predictors for the secondary risk of a cardiovascular event are age, history of symptomatic
cardiovascular disease, systolic blood pressure, high-density lipoprotein cholesterol, smoking behavior, ankle-brachial
pressure index, and creatinine level. The risk of a cardiovascular event in a patient as predicted by themodel was 0% to 10%
and 1% to 28% for the four risk categories at 1- and 5-year follow-up, respectively. The discriminating capacity of the
prediction model, indicated by the c statistic, was 0.76 (95% confidence interval, 0.71-0.80).
Conclusion: A prediction model can be used to predict secondary cardiovascular risk in PAD patients. We propose such a
prediction model to allow for the identification of PAD patients at the highest risk of a cardiovascular event or cardiovascular
death, which may be a viable tool in vascular secondary health care practice. (J Vasc Surg 2009;50:1369-77.)Peripheral arterial disease (PAD) is a substantial health
care problem in Western societies. A prevalence of 3% to
10% has been reported for the general population,1 and a
prevalence up to 29% has been reported in primary health
care populations.2 These figures will likely increase in the
coming years, due to aging and increased life expectancy,3
in part by the improved treatment of coronary artery disease
(CAD), and the increasing prevalence of diabetes mellitus.
PAD is associated with high rates of cardiovascular
events, including nonfatal myocardial infarction (MI) and
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doi:10.1016/j.jvs.2009.07.095stroke, and vascular death.2,4 Although PAD patients are
exposed to the same risk factor profile for cardiovascular
diseases as CAD patients and cerebrovascular disease
(CVD) patients,5 the incidence of future cardiovascular
events in PAD patients is higher than it is in CAD or CVD
patients.6 This is probably because a large proportion of
PAD patients also have established atherosclerotic disease
in other vascular beds6 and because PAD symptoms have a
relatively late onset.
Secondary risk management in PAD patients, which cur-
rently consists of treatment of cardiovascular risk factors and
lifestyle interventions, is therefore of particular importance.
Recent data show that appropriate risk factor control is
reached less frequently in PAD patients than it is in CAD or
CVD patients,7 stressing the need of further optimization of
cardiovascular risk factor management in PAD patients. Sec-
ondary risk factor management in PADmay also benefit from
a predictionmodel that could identify PADpatients that are at
the highest risk of a cardiovascular event. These highest-risk
PADpatients could then bemonitored and treated evenmore
intensively to prevent a secondary event. Stratifying PAD
patients according to their risk of secondary events could also
1369
JOURNAL OF VASCULAR SURGERY
December 20091370 Sprengers et alaid in achieving optimal cardiovascular risk factor manage-
ment.
Primary risk assessment has mainly been based on tra-
ditional cardiovascular risk factors. However, a prediction
model for the secondary risk in patients with overt PAD
may benefit from additional information on comorbid dis-
eases, the clinical staging of PAD, hemodynamic variables
such as the ankle-brachial index (ABI), and biologic mark-
ers.8 No prediction model for the risk of cardiovascular
events in patients with established PAD that incorporates
these characteristics is currently available. The objective of
this study was to develop such a prediction model to
identify PAD patients at the highest risk of a cardiovascular
event or cardiovascular death.
METHODS
Study population. This study used data from patients
enrolled in the Second Manifestations of ARTerial disease
(SMART) study. The SMART study is an ongoing, pro-
spective, single-center cohort study in patients with clini-
cally manifest vascular disease or cardiovascular risk fac-
tors.9 The main inclusion criteria are CAD, CVD, or PAD,
abdominal aortic aneurysm (AAA), or any or all of the
following risk factors for atherosclerosis: hyperlipidemia,
diabetes mellitus (type 1 and 2), or hypertension. Excluded
are patients with a terminal malignancy, patients not able to
live independently (Rankin scale 3), or patients who are
not sufficiently fluent in Dutch.
Since 1996, patients have been includedwhowere aged
18 to 80 years and were referred to the University Medical
Center (UMC) Utrecht, The Netherlands, for the treat-
ment of clinically manifest vascular disease or cardiovascular
risk factors. Patients underwent a vascular screening, in-
cluding a questionnaire, blood chemistry analysis, and non-
invasive laboratory testing, which included a 12-lead rest-
ing electrocardiogram (ECG), resting ABI, and ABI after a
treadmill test. Ultrasound imaging was used to measure the
juxtarenal and infrarenal anteroposterior diameter of the
aorta and the length and volume of both kidneys. Hemo-
dynamically significant stenosis of the common and internal
carotid artery was assessed with color Doppler-assisted
duplex scanning. Ultrasound imaging was used to measure
common carotid intima-media thickness, and common ca-
rotid distensibility was documented with the Wall Track
System (Pie Medical Systems, Maastricht, The Nether-
lands).
Eligible patients received written and oral information
about the goals and methodology of the study from quali-
fied research nurses or doctors at their first or second visit to
the hospital, and all patients were asked to provide written
informed consent. The study was approved by the UMC
Utrecht Medical Ethics Committee. The rationale and
design of the SMART study have been described in detail
elsewhere.9
Recruitment in the SMART study is ongoing, and
approximately 800 patients are included annually. For the
current study, analyses were limited to patients included
between September 1996 and March 2007 who were re-ferred to the UMC Utrecht for clinically manifest PAD
documented as resting ABI 0.90, postexercise ABI de-
creasing 20% in at least one leg, rest pain or gangrene/
ulcers, with signs of intermittent claudication.9 The study
included 800 patients with PAD.
Predictors. All patients underwent a noninvasive stan-
dardized diagnostic protocol on a single day at the UMC
Utrecht. Medical history, current and past smoking behav-
ior and alcohol consumption were derived from a standard-
ized health questionnaire described elsewhere.9 A physical
examination included measurement of weight and height
with the participants wearing indoor clothes and no shoes.
Diastolic and systolic blood pressure was measured twice in
most patients, while seated, in the right and left upper arm,
and the mean value was taken as the blood pressure.
The right and left ABI at rest were determined in supine
patients bymeasuring the blood pressure in the arm and the
two pedal arteries at the ankle for each side. The ratios of
the highest systolic blood pressure measured at the ankle to
the highest systolic blood pressure measured in both arms
were calculated for each leg. The ABI of the leg with the
lowest ratio is reported as lowest ABI.
Blood samples were collected after overnight fasting.
Levels were measured of total cholesterol, triglycerides,
high-density lipoprotein (HDL) cholesterol, glucose, ho-
mocysteine, creatinine, and high-sensitive C-reactive pro-
tein (hsCRP). Low-density lipoprotein (LDL) cholesterol
was calculated with the Friedewald formula when the tri-
glyceride plasma level was 4.5 mmol/L. Diabetes was
defined as a fasting plasma glucose 7.0 mmol/L, a non-
fasting serum glucose 11.1 mmol/L, or the use of oral
antidiabetic drugs or insulin.
Outcome. Patients were biannually asked to complete
a questionnaire on hospitalizations and outpatient clinic
visits. The outcome of interest was the occurrence of a
cardiovascular event comprising nonfatal MI, nonfatal
stroke, or death from vascular causes.
Nonfatal MI was defined as an event with at least two of
the following: (1) chest pain for 20 minutes not disap-
pearing after administration of nitrates, (2) ST elevation1
mm in two following leads or a left bundle branch block on
the ECG, or (3) creatine kinase (CK) elevation of at least
two times the normal value of CK and a MB-fraction 5%
of the total CK value.
Nonfatal stroke was defined as relevant clinical features
that caused an increase in handicap of at least one grade on
the modified Rankin scale, accompanied by a fresh infarct
or a hemorrhage on a repeated computed tomography
(CT) scan, or as clinical deficits that caused an increase in
handicap of at least one grade on the modified Rankin scale
for which no CT documentation was needed.
Vascular death was any sudden death, including unex-
pected cardiac death occurring 1 hour after onset of
symptoms or within 24 hours given convincing circumstan-
tial evidence, or death from stroke, MI, congestive heart
failure, or an AAA rupture.9 When a possible event was
noted, hospital discharge letters and results of relevant
laboratory and radiology examinations were collected. For
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followed to classify each event accordingly. Three members
of the SMART Study Endpoint Committee, consisting of
physicians from different departments, conducted an inde-
pendent audit of this information. In case of disagreement,
opinions of other members of the Endpoint Committee
were sought and final adjudication was based on the major-
ity of the classifications obtained. The first occurring car-
diovascular event per patient was used as an outcome event
in the prediction model.
Data analysis. Baseline characteristics of the PAD pa-
tient population included in this study are presented in
Table I. The median age was 58 years, and 66% of the
patients were men. Diabetes was present in 17%. Most
patients had intermittent claudication (Fontaine class 2),
but only 8% had critical limb ischemia (Fontaine class 3 or
4). The PAD patients had a median bodymass index (BMI)
of 25.7 kg/m2.
After a critical literature review, the 13 candidate pre-
Table I. Baseline characteristics of 800 peripheral artery
disease patients in the SMART study data
Variable
Missing
values
No. (%), or
median (IQR)
Age, y 0 58 (51-68)
Gender, male 0 526 (66)
History of symptomatic
cardiovascular diseases 0 207 (26)
Cerebrovascular disease 0 66 (8)
Coronary artery disease 0 166 (21)
Body mass index, kg/m2 2 25.7 (23.4-28.3)
Diabetes 37 137 (17)
Hypertension 12 418 (52)
Systolic blood pressure, mm Hg 0 143 (131-160)
Diastolic blood pressure, mm Hg 1 81 (74-88)
Hyperlipidemia 15 554 (69)
Total cholesterol, mmol/L 5 5.6 (4.8-6.4)
HDL-cholesterol, mmol/L 5 1.16 (0.94-1.41)
LDL-cholesterol, mmol/L 58 3.53 (2.79-4.26)
Triglycerides, mmol/L 5 1.67 (1.20-2.37)
Hyperhomocysteinemia 151 99 (12)
Homocysteine, mol/L 151 12.6 (10.2-15.5)
Smoking behavior 9
Never smoked . . . 74 (9)
Former smoker . . . 568 (71)
Currently smoking . . . 149 (19)
Alcohol consumption 12
Never used alcohol . . . 170 (21)
Former user of alcohol . . . 367 (46)
Currently using alcohol . . . 251 (31)
Fontaine classification 0
Grade 2: intermittent claudication . . . 737 (92)
Grade 3/4: critical limb ischemia . . . 63 (8)
Ankle-brachial pressure index,
lowest 16 0.69 (0.55-0.85)
Creatinine, mol/L 9 86 (75-100)
High-sensitive C-reactive protein,
mg/L 298 2.60 (1.30-5.63)
HDL, High-density lipoprotein; IQR, interquartile range (25th to 75th
percentile); LDL, low-density lipoprotein; SMART, Second Manifestations
of ARTerial disease.dictors (Table II) were selected from these characteristicsfor the prediction model. Missing values of patient charac-
teristics, comprising about 5% of all required values, were
imputed as determined by the correlation between patient
characteristics with missing values with the other variables
by means of single regression imputation. Continuous can-
didate predictors were examined for extremes, and extreme
values were truncated to the first and ninety-ninth centiles
to prevent distortion of the relationship between the can-
didate predictor and the outcome.10 Furthermore, visual
inspection of the relationship between continuous candi-
date predictors and the outcome was used to apply nonlin-
ear transformations where necessary.
The presence of previous symptomatic CAD or CVD
was summed in a single variable for previous cardiovascular
disease, with a score of 0 for no history, 1 for the presence
of either condition, and 2 if CAD and CVD were both
present in the patient’s history. Smoking behavior was
redefined into two groups, consisting of patients who never
smoked or of patients who currently smoke or had a history
of smoking, before further analysis to abolish a possible
reporting bias by patients. Next, reduction of the predic-
tion model was performed by means of backward stepwise
selection of predictors using the Akaike information crite-
rion resulting in the final (reduced) model.11
Any prediction model shows too optimistic performance—
over-fitting—in the data set from which it has been devel-
oped.12 This over-fitting can be corrected by applying a
bootstrapping technique. With this technique, the model-
ing process is repeated multiple times to validate, and if
necessary, adjust the regression coefficients of the predic-
tion model with a shrinkage factor. The final model’s
predictive performance after bootstrapping can be regarded
as the expected performance in similar future patients.
Model performance was examined by determination of
Table II. Hazard ratios and the contribution of selected
predictors to the multivariate Cox regression model (2
and df) in a full model for cardiovascular events, based on
a single imputed data set with n  800
Predictor HR (95% CI) 2 df
Age 55 years 1.9 (1.4-2.7) 14 1
Male gender 1.0 (0.7-1.6) 0.01 1
History of symptomatic
cardiovascular disease 3.0 (1.6-5.5) 11 1
Body mass index 0.9 (0.7-1.1) 2 1
Diabetes 1.3 (0.8-2.0) 1 1
Systolic blood pressure 1.2 (0.9-1.5) 2 1
High-density lipoprotein cholesterol 0.8 (0.6-1.0) 3 1
Homocysteinea 1.2 (0.9-1.6) 2 1
Current or former smoker 2.0 (1.0-4.0) 4 1
Fontaine classification grade 3/4:
CLI 1.2 (0.6-2.1) 0.24 1
Ankle-brachial pressure index 0.7 (0.6-1.0) 5 1
Creatinine 1.2 (1.1-1.3) 10 1
High-sensitive C-reactive protein 1.1 (1.0-1.2) 1 1
CI, Confidence interval; CLI, critical limb ischemia; df, degrees of freedom;
HDL, high-density lipoprotein; HR, hazard ratio.
aLogarithmic transformation.the model’s discrimination and calibration. Discrimination
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guish between patients who will experience the outcome
and those who will not. Discrimination was assessed by
calculating the concordance (c) statistic with 95% confi-
dence intervals (CIs). The interpretation of the c statistic is
equivalent to the area under the receiver operating charac-
teristic curve; that is, a c statistic of 0.5 indicates no discrim-
ination above chance, whereas a c statistic of 1.0 indicates
perfect discrimination. Model calibration—the agreement
between predicted risks and observed risks—was assessed
by comparing the predicted survival and the observed sur-
vival at the 1- and 5-year follow-up.
To facilitate the calculation of the individual risk, a
score chart was created by dividing each regression coeffi-
cient by the smallest regression coefficient and rounding it
to the nearest integer. The sum of scores of all predictors
was used to classify the patient in one of four risk categories,
each of which has been linked to the risk of a cardiovascular
event during 1 and 5 years of follow-up.
All variables were handled in an SPSS 16.0 data sheet
(SPSS Inc, Chicago, Ill). Analyses were performed using R
2.7.2 software (R Foundation for Statistical Computing,
Vienna, Austria).
RESULTS
Study population. The analyses included 800 PAD
patients. Baseline characteristics are presented in Table I.
The mean follow-up was 4.7 years (range, 0-10 years). Full
follow-up data were available for 95.9% of patients. At some
time during the study, 33 patients (4.1%) were lost to
follow-up, but partial data were available for these patients
out to a mean follow-up of 1659 days (range, 215-3420
days). A total of 120 events occurred (27% nonfatal MI,
21% nonfatal stroke, and 52% mortality from vascular
causes) corresponding to a 1- and 5-year cumulative inci-
dence of 3.1% and 13.2%, respectively.
Predictionmodel andmodel performance. According
to the visual inspection of the relationship between age and
outcome, no age effect was assumed for age55 years, but
a linear age effect was assumed for age 55 years. In
addition, a logarithmic transformation was applied for ho-
mocysteine. All other selected continuous predictors were
added to the model as linear variables. The full main effects
model had a model 2 of 146 and an R2 value of 0.154.
Predictors with a large prognostic strength were age (2,
14), a history of symptomatic cardiovascular diseases (2,
11), and plasma levels of creatinine (2, 10).
Backward stepwise model reduction resulted in sex,
BMI, diabetes, homocysteine, Fontaine classification, and
hsCRP being dropped from the model. After 100 repeats,
the bootstrap procedure resulted in a shrinkage factor of
0.88, which was used to correct the regression coefficients
for over-fitting. Predictors and corrected regression coeffi-
cients in the final model are presented in Table III. The R2
value of the final model was 0.147.
The discriminating capacity of the final model, as indi-
cated by the c statistic, was 0.76 (95% CI, 0.71-0.80). To
provide an indication of the calibration of themodel, Table IVreports the number of study patients across the four risk
categories of the risk score and the observed number of
events.
Score chart. The Fig shows the score chart for predict-
ing the risk of a cardiovascular event at 1 year and 5 years.
After adding the scores for each predictor, the sum score
will classify the patient in one of the four predicted risk
categories. As an example of how to use this score chart, a
man aged 60, with a systolic blood pressure of 135mmHg,
a resting ABI of 0.83, an HDL level of 1.00 mmol/L, a
creatinine level of 130 mol/L, and a history of coronary
artery disease, who quit smoking 5 years ago receives a
score of: 40 (years55 8) 86 (CAD and no history of
CVD)  135 (systolic blood pressure)  107 (former
smoker)  130 (creatinine level) – 74 (HDL  74) – 130
(ABI 157) 294 points. This score places the patient in
the third risk category with a 1-year and 5-year estimated
risk of a cardiovascular event of 3% and 12%, respectively.
Table IV presents the number of study patients across
the four risk categories of the risk score and the observed
number of events. Respectively, zero (0%) and one patient
(1%) in the low-risk group experienced an event after 1 and
5 years of follow-up, whereas 13 (10%) and 37 patients
(28%) in the very-high risk group experienced an event after
1 and 5 years of follow-up. These risk categories can be used
Table III. Corrected regression coefficients of the
predictors in the stepwise backward selected model
Predictor Regression coefficient (95% CI)
Age 55 years 0.0489 (0.0426 to 0.0690
History of symptomatic
cardiovascular diseases, 0-2 0.5105 (0.4281 to 0.7369)
Systolic blood pressure 0.0059 (0.0026 to 0.0110)
High-density lipoprotein
cholesterol –0.4368 (–0.7804 to –0.2164)
Current or former smoker 0.6318 (0.3788 to 1.0630)
Ankle-brachial pressure index –0.9296 (–1.5014 to –0.6200)
Creatinine 0.0068 (0.0063 to 0.0095)
CI, confidence interval.
Table IV. Number of patients with and without an event
during 1-year and 5-year follow-up across the categories
of the risk score compared with the risk before the
application of the model
Risk score
Total patients
(n  800)
No. (%)
1-year FU
Event (n  24)
No. (%)
5-year FU
Event (n  84)
No. (%)
1. Low 91 (11) 0 (0) 1 (1)
2. Moderate 340 (43) 4 (1) 17 (5)
3. High 239 (30) 7 (3) 29 (12)
4. Very high 130 (16) 13 (10) 37 (28)
Risk without application of
the prediction model
3.1% 13.2%
FU, Follow-up.to identify patients at low and high risk.
ictor
d t is
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Patients with PAD experience a higher rate of cardio-
vascular events death caused by an atherothrombotic event,
such as MI and stroke, than patients with other primary
Fig. Score chart for the 1-year and 5-year predicted risk
calculated by S(t)  S0(t)exp(LP), where the linear pred
predictor and  the regression coefficient (Table III), anmanifestations of atherosclerotic disease.6 The presence ofseveral risk factors and comorbidity within the PAD group
importantly contributes to this high risk. This warrants
strict risk factor treatment of all PAD patients according to
the current international guidelines. In this study we devel-
cardiovascular event. The exact survival estimate can be
(LP) is 1  x1  2  x2  . . ., with x denoting the
the time point of interest.of aoped a prediction rule to identify those PAD patients that
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year and 5 years of follow-up.
From the traditional risk factors included in the model,
male sex, obesity (BMI), and diabetes were dropped as
predictors for a secondary cardiovascular event during the
stepwise backward selection procedure. Studies show these
risk factors contribute to the development of atherosclero-
sis and to the prediction of a primary cardiovascular event,
but they do not contribute to the risk prediction of a
secondary cardiovascular event in PAD patients in our
model. A possible explanation for this could be that these
risk factors are involved in the etiology of atherosclerosis
but are less significant in its progression. In fact, male sex
has been associated with better risk factor management in
patients with established atherosclerotic disease,7 which in
turn could slow disease progression. Furthermore, in a
large, international study on the 1-year cardiovascular event
rate in a stable outpatient population similar to the SMART
cohort, correction for obesity (BMI) did not substantially
affect this 1-year event rate.6
From the nonclassical risk factors for which an addi-
tional predictive effect has been suggested in the literature,
blood homocysteine level, Fontaine classification, and
hsCRP level were dropped from the final model. The
association between homocysteine levels and the severity of
atherosclerosis, progression of the disease, and mortality
rates has been discussed in several retrospective and pro-
spective studies,13 and folic acid and B-vitamin supplemen-
tation have been proposed as treatment for hyperhomocys-
teinemia. More recent studies, however, indicate that
although such therapy significantly lowers homocysteine
levels, it has no effect on vascular inflammation14 or the risk
of a cardiovascular event.15 These observations are in line
with our finding that homocysteine has no additive contri-
bution to the prediction of a secondary cardiovascular event
in PAD patients. We note that this concerns the predictive
value of homocysteine levels at baseline, and that no con-
clusions can be drawn from this research about the effects of
therapy to lower homocysteine on the progression of the
disease.
Elevated CRP levels have also been associated with the
occurrence of cardiovascular events and appear to contrib-
ute to the risk prediction of recurrent cardiovascular events
in patients with coronary heart disease.16 Data are limited
on the added value of CRP to the risk prediction of second-
ary cardiovascular events in PAD patients. One prospective
study demonstrated that high levels of CRP were indepen-
dently associated with future cardiovascular events in PAD
patients.17 This contradicts our findings that CRP levels did
not have a significant contribution to the prediction of
secondary events in PAD patients. The difference might be
explained by the fact that our end point does not include
revascularization procedures, whereas coronary and lower
extremity revascularizations comprised most of the events
in the combined end point of this other study. Further-
more, a possible publication bias for negative results on the
association between CRP levels and cardiovascular events
might explain the still limited number of publications onthis topic. On the other hand, an association of CRP levels
with renal function has been reported.18,19 The predictive
value of CRP might therefore already be contained in the
predictive value of the creatinine level. Creatinine, being
the strongest predictor of both, was kept in the model
during backward selection.
Clinical disease staging for the severity of PAD had
additional value in secondary risk prediction. Clinicians use
the Fontaine classification to designate patients as asymp-
tomatic and symptomatic and to subdivide symptomatic
patients into groups according to the severity of their
complaints. The prognosis of patients with critical limb
ischemia (Fontaine classification grade 3 and 4) is substan-
tially worse than the prognosis of patients with intermittent
claudication (Fontaine classification grade 2); therefore,
the use of the Fontaine classification as a possible predictor
for future cardiovascular events has been suggested. How-
ever, the Fontaine classification was dropped in the stepwise
backward selection procedure during the development of
our final model. A possible explanation for this is that the
number of patients with critical limb ischemia in our cohort
was rather small (8% of all patients). Such a limited number
of cases in one group of a dichotomous variable may abolish
its predictive effect.
Furthermore, the ABI, as another marker for the sever-
ity of PAD, provided additional predictive information in
our model. The information provided by the Fontaine
classification might contain similar information as the
stronger predictor ABI. The finding that the ABI has a
predictive value in our model is consistent with several
cohort studies demonstrating a strong association between
decreased ABI and an increased occurrence of fatal and
nonfatal cardiovascular events.
Generalizability. The prediction rule has been devel-
oped on a heterogeneous, white majority population of
PAD patients referred from primary care to secondary
health care and may therefore be a viable tool in any
vascular secondary health care practice. The model was
developed from data of patients with established PAD who
participated in the SMART study after their referral to
UMC Utrecht. The patient characteristics of our study
population (Table I) are comparable with those of other
PAD populations, and we have no reason to assume that
the study population used for the development of our
prediction model was a selective group of patients. Further-
more, the exclusion criteria for the SMART study only
exclude patients with a terminal malignancy, an inability to
live independently, or those who are insufficiently fluent in
Dutch. It is therefore unlikely that the generalizability of
our prediction model to other PAD populations is thereby
hindered.
The number of missing values was limited (5%) for
most baseline characteristics (Table I). Missing values for
homocysteine and CRP occurred because these variables
were not routinely measured during the first years of the
study. These data are therefore “missing completely at
random.”20 The relative high fraction of missing values for
LDL is related to the use of the Friedewald formula, with
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plasma level is 4.5 mmol/L. These missing LDL values
are “missing at random.”20 The missing values listed in
Table I do therefore not hinder the generalizability or
validity of our prediction model.
During the development of the model, however, the
regression coefficients were shrunk to correct for over-
fitting and the generalizability (external validity) has not
been tested in other populations than the SMART cohort.
Therefore, generalizability testing in other populations
should be considered before implementation of the model
in clinical practice.
Score chart. The score chart was developed to provide
vascular surgeons and vascular internists with an easy tool
to identify newly referred PAD patients at a high risk of a
fatal or nonfatal MI or stroke. The elevated risk of second-
ary cardiovascular events warrants strict treatment of car-
diovascular risk factors in all PAD patients. The prediction
rule we developed could serve as a useful tool to identify the
highest-risk patients, who could subsequently be referred
for an extensive workup to identify—and when required
and possible to treat—high-grade stenosis in coronary and
carotid arteries to prevent these adverse outcomes.
Although the prediction rule allows the calculation of
the cardiovascular risk at an individual patient level, we
linked the score to risk categories, which may facilitate the
decision of whether to refer a patient for an extensive
workup. We have labeled the four categories as low, mod-
erate, high, and very high risk. If patients with a low or
moderate score (225) would be categorized as being at a
lower risk and therefore would be treated according the
current guidelines, 54% of all PAD patients would not be
referred for an extensive workup, yet a cardiovascular event
would occur in four patients (0.5%) during the 1-year
follow-up and in 18 (2.3%) by 5 years. With a score of 225
as a cutoff for referral, the prediction model has a sensitivity
of 83% and 79% at 1 and 5 years and a specificity of 55% and
58%, respectively.
These figures imply that a rather large number of
patients need to be referred for an extensive workup as a
result of a high predicted risk of a cardiovascular event by
the model without actually experiencing such event (posi-
tive predictive value of 5.4% and 17.9% for 1-year and
5-years of follow-up). More important, however, the num-
ber of patients not referred for an extensive workup who
will actually experience a cardiovascular event is low, with
negative predictive values of 99.1% and 95.8% for 1-year
and 5-years of follow-up. Five to 15 patients need to be
referred for an extensive workup to find one high-risk
patient that should (if possible) be treated to prevent sec-
ondary cardiovascular disease.
To date, no prediction model for assessing the second-
ary risk of a cardiovascular event in PAD patients has been
developed, and besides the preoperative screening of PAD
patients eligible for surgery, screening, and referral of other
PAD patients is generally not performed. Therefore, refer-
ral of the very-high-risk group only (cutoff score 350)
could already reduce the number of occurring secondarycardiovascular events, while the number of patients referred
for an extensive workup remains limited. When only the
very-high-risk group is referred, 16% of all PAD patients
will be referred for an extensive workup. In the group not
referred for workup, 11 (1.6%) and 47 (7.0%) cardiovascu-
lar events will occur at the 1-year or 5-year follow-up,
respectively. With a cutoff value of 350, the prediction
model has a sensitivity at 1 year and 5 years of follow-up of
54% and 44% and a specificity of 85% and 87%, respectively.
When only the very-high-risk group is referred, two pa-
tients need to be referred for an extensive workup to find
one high-risk patient who should be treated to prevent a
secondary cardiovascular disease.
Despite the number of events being too limited to
allow for accurate long-term risk prediction, the chart of
the Fig clearly illustrates the fate of PAD patients across the
four risk categories for follow-up times 5 years. The
number of event-free patients categorized by the model as
being at low risk (categories 1 and 2) visibly secedes from
the number of event-free patients who were categorized as
being at high risk (categories 3 and 4) at 10 years of
follow-up. These trends underline the need for risk strati-
fication for cardiovascular events in PAD patients.
Extensive workup. The extensive workup we men-
tion in this article should ideally be aimed at identifying the
presence of pathology that may result in a cardiovascular
event, such as a high-grade stenosis in the coronary or
carotid arteries or cardiac arrhythmia. The discussion about
what imaging modality, for example, carotid ultrasound
scans, stress test, or angiography, should be used for these
examinations might be strenuous but is beyond the scope
of this article. We note, however, that a possible increase in
morbidity and death resulting from interventions per-
formed as part of an extensive workup are currently not
incorporated into this prediction rule.
Nevertheless, further optimization of the treatment of
PAD patients and, in particular, the treatment of patients at
the highest risk remains advantageous and might benefit
from taking secondary risk stratification into account. Ex-
emplary, setting even more strict targets for risk factor
reduction (lower lipid plasma levels, lower blood pressure,
steady blood glucose levels, absolute smoking cessation,
more overweight reduction) for the highest-risk patients,
for instance, might already prove to be an effective “exten-
sive workup.” Moreover, stratifying PAD patients accord-
ing to their risk of a secondary event could aid in achieving
improved therapy compliance.
CONCLUSIONS
We developed a prediction model for patients with
established PAD to identify PAD patients at the highest risk
of a cardiovascular event or cardiovascular death. The
model has a high sensitivity for risk stratification at 1 and 5
years. Important predictors for the secondary risk of a
cardiovascular event are age, history of symptomatic cardio-
vascular disease, systolic blood pressure, HDL cholesterol,
smoking behavior, ABI, and creatinine. We believe this is
the first predictionmodel for future cardiovascular events in
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December 20091376 Healypatients with established PAD and that it may be a viable
tool in vascular secondary health care practice.
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The authors have studied a cohort from the SMART (Secondary
Manifestations of ARTerial Disease) study for the purpose of identi-
fying risk factors associated with stroke, myocardial infarction, and
death in patients with peripheral arterial disease. They suggest that
identifying very high risk patients could lead to interventions that
would reduce cardiovascular morbidity andmortality. Eight hundred
patients were identified who met their criteria, estimated to be about
10% of the patients recruited in the SMART study at the time of
enrollment. They were able to construct a scoring system based on
eight variables that separates peripheral arterial disease patients into
four risk categories. The very high risk patients had a 10% risk of
stroke, myocardial infarction, or death at one year, and a 28% risk ofsystem developed for peripheral arterial disease patients and could be
a valuable screening tool for clinicians.
Although the study population was heterogeneous, all pa-
tients were from the Netherlands and the scoring system may not
apply to other populations across the world. The SMART study is
prospective and the authors have appropriately utilized statistical
modeling, but this scoring system will require validation on other
populations to confirm the authors’ findings.
The authors’ intent was to develop a scoring system that
would identify very high risk patients whomight benefit frommore
aggressive evaluation and treatment. They suggest that secondary
cardiovascular events (stroke, myocardial infarction, and death)
might be reduced with more extensive work-up of the very high
